Investment Rating - The investment rating for the industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index experienced a decline of 3.17%, ranking 22nd among 31 primary industries, underperforming the CSI 300 index which fell by 1.25% [6][17] - The valuation of the pharmaceutical and biotechnology industry as of February 6, 2026, is a PE (TTM overall method, excluding negative values) of 29.57x, down from 30.31x in the previous period, indicating a downward trend below the average [6][22] - The top three sub-industries in terms of PE (TTM overall method, excluding negative values) are vaccines (46.30x), hospitals (43.34x), and medical consumables (37.71x), while pharmaceutical distribution has the lowest valuation at 14.88x [22] Industry Trends - The focus in the global pharmaceutical market continues to be on GLP-1 targets, with Eli Lilly's tirzepatide establishing a leading position in the metabolic disease field due to its clinical value and commercialization performance [9] - The collaboration model between multinational pharmaceutical companies and Chinese biopharmaceutical firms is evolving towards "platform capabilities + multi-project combinations," highlighting the long-term strategic value of underlying innovative capabilities such as sustained delivery technology and peptide R&D platforms [9] - The investment logic in the industry is shifting from single blockbuster products to platform-based, matrixed approaches that extend into critical supply chain segments [9] Investment Recommendations - Focus on innovative pharmaceutical companies with "core technology platforms + diversified pipelines," as their ability to derive multiple values from platforms and realize cross-border cooperation milestones will be a key advantage [9] - Pay attention to industry chain segments benefiting from drug long-acting and oral trends, including complex formulation processes, high-end delivery technologies, and related peptide CDMO fields [9] - In the context of strong global R&D and production demand, peptide CXO companies that are active in cross-border collaborations, have balanced customer structures, and possess solid compliance systems will continue to share in the industry's high prosperity dividends [9]

Investment Rating - The investment rating for the industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index experienced a decline of 3.17%, ranking 22nd among 31 primary industries, underperforming the CSI 300 index which fell by 1.25% [6][17] - The valuation of the pharmaceutical and biotechnology industry as of February 6, 2026, is a PE (TTM overall method, excluding negative values) of 29.57x, down from 30.31x in the previous period, indicating a downward trend below the average [6][22] - The top three sub-industries in terms of PE (TTM overall method, excluding negative values) are vaccines (46.30x), hospitals (43.34x), and medical consumables (37.71x), while the median is 32.64x, with pharmaceutical distribution having the lowest valuation at 14.88x [22] Industry Trends - The focus in the global pharmaceutical market is on GLP-1 targets, with Eli Lilly's Tirzepatide establishing a leading position in the metabolic disease field due to its clinical value and commercialization performance [9] - The collaboration model between multinational pharmaceutical companies and Chinese biopharmaceutical firms is evolving towards "platform capabilities + multi-project combinations," highlighting the long-term strategic value of underlying innovative capabilities such as sustained delivery technology and peptide R&D platforms [9] - The investment logic in the industry is shifting from single blockbuster products to platform-based, matrixed approaches, and key supply chain segments [9] Investment Recommendations - Focus on innovative pharmaceutical companies with "core technology platforms + diversified pipelines," as their ability to derive multiple values from platforms and achieve cross-border collaboration milestones will be a key advantage [9] - Pay attention to industry chain segments benefiting from drug long-acting and oral trends, including complex formulation processes, high-end delivery technologies, and related peptide CDMO fields [9] - In the context of strong global R&D and production demand, peptide CXO companies that are active in cross-border collaborations, have balanced customer structures, and possess solid compliance systems will continue to share in the industry's high prosperity dividends [9]

Core Viewpoint - Fuhong Hanlin (02696) has seen its stock price increase by over 24% in February, with a recent rise of 5.67% to HKD 70.85, driven by a strategic partnership with Eisai Co., Ltd for the commercialization of the anti-PD-1 antibody, Surufatinib, in Japan [1] Group 1: Partnership Details - Eisai and Fuhong Hanlin have entered into an exclusive commercialization agreement for Surufatinib in Japan, which includes a USD 75 million upfront payment, potential regulatory milestone payments up to USD 80.01 million, and sales milestone payments up to USD 233.3 million [1] - Fuhong Hanlin will also receive a double-digit percentage royalty based on product sales [1] Group 2: Strategic Decisions - Fuhong Hanlin's CEO, Dr. Zhu Jun, indicated that the company has been strategically preparing for the Japanese market for three years, initially planning to independently launch and commercialize the product [1] - The decision to partner with Eisai was influenced by the "very sincere" offer made by Eisai, leading to a shift from their original plan [1]

Core Viewpoint - Fuhong Hanlin (2696.HK) has seen a significant stock price increase of over 8% on February 10, with a total rise of 30% over six days, indicating a reversal trend and a current market value of HKD 39.6 billion [1] Group 1: Company Developments - Fuhong Hanlin has completed the full circulation of H-shares, which is expected to enhance its global strategy and attract more international investors, benefiting long-term development and shareholder interests [1] - At the JPM 2026 conference, the company showcased its "Globalization 2.0" strategy, outlining future innovation pipeline and development plans, with over 40 new clinical research applications expected to be approved in the next five years [1] - By 2030, the company anticipates having over 20 products launched globally, with 15 expected to enter the European and American markets [1] Group 2: Product Pipeline and Collaborations - The company plans to commercialize more Antibody-Drug Conjugates (ADCs), bispecific antibodies, and T-cell engagers (TCEs), targeting four major therapeutic areas: oncology, autoimmune diseases, metabolism, and central nervous system disorders [1] - Fuhong Hanlin has entered into an exclusive commercialization agreement with Eisai Co., Ltd. for the anti-PD-1 antibody, Surulitinib, in the Japanese market, which includes an upfront payment of USD 75 million and potential milestone payments totaling up to USD 800.1 million, along with royalties based on product sales [1]

Core Viewpoint - Fuhong Hanlin (2696.HK) has seen a significant stock price increase of over 8%, with a total rise of 30% over six days, currently trading at HKD 72.7, with a market capitalization of HKD 39.6 billion [1] Group 1: Company Developments - Fuhong Hanlin has completed the full circulation of H-shares, which is expected to enhance liquidity and support its globalization strategy, thereby unlocking long-term investment value [1] - The company showcased its "Globalization 2.0" strategy at the JPM 2026 conference, outlining its future innovation pipeline and development plans [1] - Over the next five years, Fuhong Hanlin anticipates more than 40 new clinical research applications to be approved, with over 20 products expected to be launched globally by 2030, 15 of which are projected to enter the European and American markets [1] Group 2: Product Pipeline and Collaborations - The company plans to commercialize more Antibody-Drug Conjugates (ADC), bispecific antibodies, and T-cell engagers (TCE) across four therapeutic areas: oncology, autoimmune diseases, metabolism, and central nervous system disorders [1] - Fuhong Hanlin has entered into an exclusive commercialization agreement with Eisai Co., Ltd. for the anti-PD-1 antibody, Surulitinib, in the Japanese market, along with a joint exclusive development and production licensing agreement [1] - Eisai will pay Fuhong Hanlin an upfront payment of USD 75 million, with potential regulatory milestone payments up to USD 80.01 million, and sales milestone payments up to USD 233.3 million; Fuhong Hanlin will also receive a double-digit percentage royalty based on product sales [1]

Group 1 - The core viewpoint of the article highlights the significant rise in the stock price of Fuhong Hanlin (02696), which has increased over 24% in the month, with a current price of 70.85 HKD and a trading volume of 338 million HKD [1] Group 2 - On February 5, 2023, Eisai Co., Ltd. and Fuhong Hanlin announced an exclusive commercialization agreement for the anti-PD-1 antibody, Surufatinib, in the Japanese market, along with a joint exclusive development and production licensing agreement [1] - Eisai will pay Fuhong Hanlin an upfront payment of 75 million USD, with potential regulatory milestone payments up to 80.01 million USD, and sales milestone payments that could reach up to 233.3 million USD [1] - Fuhong Hanlin will also receive a double-digit percentage royalty based on product sales [1] Group 3 - On February 6, 2023, Dr. Zhu Jun, the Executive Director and CEO of Fuhong Hanlin, stated that the company had been strategically preparing for the Japanese market for three years and had formed a local team [1] - The decision to collaborate with Eisai instead of pursuing independent commercialization was influenced by the "very sincere" offer made by Eisai [1]

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The proportion of driver gene-negative non-small cell lung cancer (NSCLC) patients is approximately 31% in both China and the United States, indicating a significant market opportunity for treatments targeting this demographic [2][15] - The estimated market size for immune drugs used in first-line treatment of driver gene-negative NSCLC is projected to be around 7.5 billion CNY (approximately 1.1 billion USD) in China and 18 billion CNY (approximately 2.7 billion USD) in the United States by 2030 [2] - The current first-line treatment for advanced driver gene-negative NSCLC primarily relies on PD(L)-1 inhibitors combined with chemotherapy, but there are limitations in long-term efficacy and options for patients intolerant to chemotherapy [3] Summary by Sections Section 1: NSCLC Global Overview - Lung cancer is the leading cancer type globally, with new cases accounting for approximately 12% of all cancer cases in 2022, translating to about 2.5 million new lung cancer cases [10] - In China, lung cancer represents about 22% of new cancer cases, with approximately 1.06 million new cases in 2022 [10] Section 2: Market Potential for Driver Gene-Negative NSCLC - The report highlights the significant market potential for immune therapies in treating driver gene-negative NSCLC, with a focus on the limitations of current treatment options [2][3] Section 3: Next-Generation Immunotherapy Approaches - The report discusses the advancements in dual (multi) antibody therapies and immune-oncology (IO) combined with antibody-drug conjugates (ADC), emphasizing their potential to improve treatment outcomes for patients with driver gene-negative NSCLC [5][8] - The clinical data supporting these new therapies is expected to catalyze further investment and development in this area [5] Section 4: Treatment Guidelines Comparison - The report compares treatment guidelines for driver gene-negative NSCLC between the United States and China, noting differences in treatment stratification and recommended therapies [32][34] - The U.S. guidelines emphasize PD-L1 expression levels, while Chinese guidelines focus more on performance status (PS) [32][34] Section 5: Future Catalysts - Key upcoming clinical data releases and studies are highlighted as potential catalysts for investment opportunities in the sector, particularly regarding dual antibodies and ADC therapies [5][8]

Core Insights - The Hong Kong stock market for innovative drugs is experiencing a strong rally, with the Hong Kong Stock Connect Innovative Drug ETF (159570) rising over 3% and achieving a trading volume exceeding 1.3 billion yuan yesterday and over 1 billion yuan today, bringing its total size to over 25 billion yuan [1][3]. Group 1: Market Performance - The innovative drug sector has seen significant interest, with the ETF's latest scale leading among its peers [1]. - Notable stocks within the ETF, such as Rongchang Biopharmaceutical and Zai Lab, have reported gains exceeding 6%, while others like Innovent Biologics and CSPC Pharmaceutical have also shown strong performance [4][5]. Group 2: Recent Developments - Recent collaborations in the innovative drug sector include a partnership between Fuhong Hanlin and Eisai for the commercialization of the anti-PD-1 monoclonal antibody, with an upfront payment of $75 million and potential milestone payments totaling up to $300 million [3]. - Yunding Xinyao announced the approval of Etrasimod for the treatment of moderate to severe active ulcerative colitis in China, following a $224 million deal for exclusive rights in Greater China and South Korea [3]. - Innovent Biologics has entered a strategic collaboration with Eli Lilly to advance global R&D in oncology and immunology, with an upfront payment of $350 million and potential milestone payments of up to $8.5 billion [3]. Group 3: Analyst Recommendations - Analysts from Kaiyuan Securities suggest increasing allocation to the innovative drug sector, highlighting the valuation attractiveness of quality stocks and the potential for significant returns from companies with strong clinical data and overseas expansion prospects [4]. - The report emphasizes the importance of focusing on innovative drugs that have shown resilience and potential for growth, particularly in the context of upcoming earnings reports in 2025 and early 2026 [6].

研究报告 Research Report 9 Feb 2026 香港医疗 Hong Kong Health Care 医药行业周报（2026.02.02-2026.02.06）：市场情绪回暖；看好基本面表现强劲的创新药产业链龙头 Healthcare Weekly (2026.02.02-2026.02.06): Market Sentiment Warms; Bullish on Leaders in Innovative Drug Chain with Strong Fundamentals [Table_yemei1] 观点聚焦 Investment Focus | [Table_Info] | | | | | --- | --- | --- | --- | | 股票名称 | 评级 | 股票名称 | 评级 | | 百济神州 | Outperform 华润医药 | | Outperform | | 京东健康 | Outperform 国药控股 | | Neutral | | 药明生物 | Outperform 映恩生物 | | Outperform | | 信达生物 | Outperform 金斯瑞生物科 ...

Group 1 - The core viewpoint of the report is that Fosun Pharma (02196) is expected to achieve net profits of 3.32 billion yuan, 4.68 billion yuan, and 4.77 billion yuan from 2025 to 2027, with year-over-year growth rates of +19.9%, +40.8%, and +2.1% respectively, indicating a positive long-term outlook and a "buy" rating maintained by Yuanta Securities [1] - The company’s subsidiary, Fuhong Hanlin, has granted Eisai the rights for the development, production, and commercialization of the PD-1 monoclonal antibody, Surulitinib, in Japan, with a total upfront payment and milestone payments potentially reaching up to $155.01 million [1] - The upfront payment includes $75 million and up to $80.01 million in regulatory milestone payments, along with potential sales milestone payments of up to $23.33 million based on annual net sales in Japan [1] Group 2 - Surulitinib, a PD-1 monoclonal antibody developed by the company, was launched in China in March 2022 and is expected to generate revenue of 1.31 billion yuan in 2024, reflecting a year-over-year growth of +17.2% [2] - The product has received EU approval for first-line treatment of SCLC in February 2025, making it the first PD-1 monoclonal antibody approved in the EU for this indication, and has also been approved in several other countries, enhancing its international market presence [2] - The company is actively expanding into new markets and indications, with ongoing clinical trials for Surulitinib in various cancers and a new application for gastric cancer treatment expected to be accepted by the Chinese regulatory authority by December 2025 [3]